Boundless Bio, Inc.
BOLDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Boundless Bio, Inc. (BOLD) is listed under Biotechnology. Valued at $54.5M, BOLD is a micro-cap name in its sector. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Market Cap
$54.5M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-2.41
EPS (TTM)
$-2.85
EPS (Fwd)
$-0.98
ROE
-67.9%
ROA
-32.8%
Cash
$72.6M
Total Debt
$0
Free CF
-$30.6M
52W Change
58.4%
Annual Financials
Cash vs Debt
Where BOLD stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BOLD finished 12.50% above its 150-day moving average ($2.08) and 26.49% above its 200-day moving average ($1.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BOLD overbought or oversold?
At the October 19, 2026 close, BOLD's RSI(14) was 29.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Boundless Bio, Inc. reports $72.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$30.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -67.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
BOLD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Boundless Bio, Inc. and its sector.